. 2018 Sep 27;18:934. doi: 10.1186/s12885-018-4835-2

Table 2.

Schedule of study assessments

Time (week no.)	-2 to 0	0	1	2	3	4	5	6	7	8	9	10	11	12	13	17
Enrollment
Eligibility screen	X
Informed consent	X
Randomization		X
Intervention			X---------------------------------------------------------------------------------------------------------------------------X
Physical tests and examinations
30s-CST (primary outcome)	X								X						X	X
6MWT	X								X						X	X
Handgrip strength	X								X						X	X
Gait speed test	X								X						X	X
Physical activity^a	X														X
DXA	X														X
BI	X														X
Body weight^a	X								X						X	X
Inflammatory biomarkers	X								X						X	X
PROMs
PRPS	X								X						X	X
MDASI^a	X								X						X	X
EORTC-QLQ-C30	X								X						X	X
HADS	X								X						X	X
Qualitative exploration
Individual Interviews															X
Feasibility
Adherence	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Attrition	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Adverse events	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Oncological treatment
Treatment related toxicity^b	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Dose-reductions^b	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Hospitalizations	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Survival	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X

^aOnce weekly for participants in the intervention group ^bRegistered for every treatment course

Abbreviations: 30s-CST 30-s chair stand test, 6MWT six-minute-walk-test, BI bioelectrical impedance, DXA whole-body dual-energy x-ray absorptiometry, EORTC-QLQ-C30 European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30, HADS Hospital Anxiety and Depression Scale, MDASI M.D. Anderson Symptom Inventory, PRPS patient-reported performance status